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Centrally acting muscle relaxants (CMRs) are often used to
alleviate musculoskeletal pain. Among them, eperisone hydro-
chloride is the most popular in Japan.1 Although it is a well-
tolerated drug,2 allergic reactions to eperisone have been re-
ported, most of which are anaphylactic or urticarial reactions.1
Acute generalized exanthematous pustulosis3 and ﬁxed drug
eruption4 are reported rare manifestations of eperisone-induced
drug eruption. Tolperisone hydrochloride, an analog of eperisone
hydrochloride, is another CMR often used in European countries.
Ribi et al. reviewed the adverse effects of tolperisone hydrochlo-
ride; almost half of the adverse effects were immediate-type hy-
persensitivity reactions.5 To date, reported CMR-related drug
eruptions have mainly been immediate-type hypersensitivity re-
actions. However, it is not clear whether this hypersensitivity is
IgE mediated, a so-called “true” type I allergic reaction. Here,
we report a case of eperisone-induced anaphylaxis in which
skin prick test (SPT) and basophil activation test (BAT) showed
negative results. An oral challenge test was the most reliable
procedure for diagnosing eperisone-induced immediate-type
hypersensitivity.
A 64-year-old woman was referred to our dermatology depart-
ment to determine potential allergens causing anaphylaxis. She
had taken eperisone hydrochloride and loxoprofen sodium,
which resulted in urticaria, throat swelling, and loss of conscious-
ness. She was taken to the emergency room, where she
responded well to administration of corticosteroids. The patient
had a history of low-back pain for which she was prescribed eper-
isone hydrochloride and loxoprofen sodium. She also had a his-
tory of bronchial asthma but not food allergy. SPT was negative
for all tested drugs, including eperisone hydrochloride and loxo-
profen sodium. Oral challenge test was negative for non-steroidal
anti-inﬂammatory drugs (NSAIDs), including aspirin (up to
500 mg), loxoprofen sodium (up to 60 mg), and paracetamol
(up to 400 mg), indicating that the patient did not have
aspirin-sensitive urticaria. Oral administration of 0.5e5 mg of
eperisone induced slight itchiness on the palms. About 90 min af-
ter oral administration of 16 mg of eperisone, the patient devel-
oped general pruritus and swelling of the face, tongue, and
palms (Fig. 1). Thus, she was diagnosed with eperisone
hydrochloride-induced anaphylaxis.
To investigate whether eperisone hydrochloride itself directly
induced basophil activation, we performed a BAT.6 Contrary toPeer review under responsibility of Japanese Society of Allergology.
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licenses/by-nc-nd/4.0/).our expectations, no increase in CD203c expression was observed
on incubation with eperisone hydrochloride (Wako Pure Chemical
Industries, Osaka, Japan) (Fig. 2). BAT with tolperisone hydrochlo-
ride (Wako Pure Chemical Industries) also induced no increase in
CD203c expression (data not shown).
Eperisone is commonly used in combination with NSAIDs.
Therefore, clinicians should determine the causative allergen in
drug eruption patients taking combinations of eperisone and
NSAIDs. In this case, because the oral challenge test for NSAIDs
was negative and oral administration of eperisone caused a hyper-
sensitivity reaction, we concluded that eperisone was the cause of
anaphylaxis. Though we did not perform challenge tests for the ex-
cipients, we suspect that eperisone itself was the causative allergenFig. 1. Eperisone-induced acute hypersensitivity reactions (a, palms; b, tongue).
vier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
Fig. 2. Basophil activation test (BAT). Peripheral blood samples from the patient and
healthy control were collected in EDTA tubes and incubated for 15 min with Ca2þ-
rich buffers, ﬂuorescent-labeled anti-human CD203c, CD3e, and CRTH2 antibodies,
and antigens (PBS, anti-IgE antibody, and eperisone hydrochloride), according to the
manufacturer's instructions (Beckman Coulter, Brea, CA, USA). After that, red blood
cells were lysed. Samples were washed with PBS, re-suspended in 0.1% PFA in PBS,
and analyzed with a FACS Verse ﬂow cytometer (BD Biosciences, San Diego, CA, USA).
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commercially available eperisone tablets, Myonal® andMyorelark®,
which have different excipients. However, our patient's BAT results
with eperisone were negative.
Hur et al. performed a BAT with aﬂoqualone, another CMR, and
reported increased expression of CD63 with aﬂoqualone stimula-
tion.7 It is generally accepted that positive BAT results in vitro indi-
cate that a hypersensitivity reaction is IgEmediated.8 A positive SPT
in vivo also provides evidence that the culprit agent induces an IgE-
mediated reaction.8 In our patient, both SPT and BAT results were
negative. In fact, most SPT for eperisone are negative, according
to the literature.1 To the best of our knowledge, there have been
no deﬁnite reports that eperisone itself induced IgE-mediated
allergic reaction.
There are several possible explanations for eperisone-induced
acute hypersensitivity reactions. First, because eperisone changes
into several metabolites in vivo, these metabolites might induce
IgE-mediated reactions. Second, because eperisone has vasodilat-
ing effects,9 hypersensitivity reactions and urticarial reactions
might have occurred as a result of rapid vasodilation by eperi-
sone in our patient. Lastly, a recent report clariﬁed the pseudo-
allergic (IgE-independent) release of histamine from mast
cells via speciﬁc receptor MRGPRX2.10 Because muscle relaxant
drugs such as tubocurarine and atracurium have been proved
as potential agonists for MRGPRX2, eperisone might also stimu-
late mast cells via MRGPRX2 to induce their degranulation
via IgE-independent fashion. In fact, our patient showed dose-
dependent side effects with administration of eperisone. Admin-
istration of 0.5e5 mg resulted in only slight itchiness on thepalms, but 16 mg of eperisone induced systemic reaction; such
dose-dependent effect of eperisone may suggest either vasodila-
tion or pseudo-allergic reaction, but not IgE-mediated type I
allergic reaction.
In conclusion, we report a case of eperisone-induced anaphy-
laxis, in which SPT and BAT were negative. Our results indicate
that eperisone itself does not directly induce IgE-mediated hyper-
sensitivity reactions. An oral challenge test is necessary to diagnose
eperisone-induced acute hypersensitivity. The exact mechanism by
which eperisone induces type I allergic reactions should be clearly
determined in the future.
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